Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Clinical Research and Equipment Industry Analysis

UpdatedAug 26, 2026
DataAggregated Company Financials
Companies22
  • 7D1.0%
  • 3M21.0%
  • 1Y23.6%
  • YTDn/a

The Clinical Research and Equipment industry has stayed flat over the last week. As for the the longer term, the industry is up 20% over the past 12 months. Earnings are forecast to grow by 22% annually.

Industry Valuation and Performance

Has the Indian Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 26 Aug 2026₹4.0t₹374.4b₹48.3b36.9x82.5x10.7x
Fri, 24 Jul 2026₹3.5t₹360.7b₹46.2b40.5x75.1x9.6x
Sun, 21 Jun 2026₹3.3t₹361.7b₹46.4b39.2x71.4x9.2x
Tue, 19 May 2026₹3.3t₹358.0b₹44.2b33.4x74.9x9.2x
Thu, 16 Apr 2026₹3.0t₹350.2b₹46.2b30.6x64.9x8.6x
Sat, 14 Mar 2026₹2.9t₹350.2b₹46.2b27.4x61.9x8.2x
Mon, 09 Feb 2026₹2.8t₹345.8b₹46.2b29.4x61.1x8.2x
Wed, 07 Jan 2026₹3.2t₹342.6b₹48.4b33.6x66.1x9.3x
Fri, 05 Dec 2025₹3.1t₹342.6b₹48.4b32.7x64.4x9.1x
Sun, 02 Nov 2025₹3.3t₹332.5b₹45.6b45x72x9.9x
Tue, 30 Sep 2025₹3.0t₹331.4b₹45.5b43.1x66.1x9.1x
Thu, 28 Aug 2025₹3.2t₹331.4b₹45.5b40.9x70.4x9.7x
Sat, 26 Jul 2025₹3.3t₹320.3b₹41.8b53.5x79.1x10.3x
Mon, 23 Jun 2025₹2.8t₹299.7b₹37.2b46x76.1x9.5x
Wed, 21 May 2025₹2.8t₹295.2b₹32.8b47.7x84x9.3x
Fri, 18 Apr 2025₹2.5t₹287.4b₹30.8b47.1x82.2x8.8x
Sun, 16 Mar 2025₹2.5t₹287.4b₹30.8b47x79.9x8.6x
Tue, 11 Feb 2025₹2.6t₹286.2b₹30.2b52.1x87.5x9.2x
Thu, 09 Jan 2025₹2.5t₹269.1b₹30.1b54.4x84.5x9.4x
Sat, 07 Dec 2024₹2.5t₹254.2b₹28.8b52.4x85.7x9.7x
Mon, 04 Nov 2024₹2.4t₹247.9b₹26.0b48.8x91.8x9.6x
Wed, 02 Oct 2024₹2.3t₹247.6b₹26.3b52.6x87.5x9.3x
Fri, 30 Aug 2024₹2.1t₹247.6b₹26.3b47.2x80.9x8.6x
Sun, 28 Jul 2024₹1.9t₹201.7b₹23.8b41x79.8x9.4x
Tue, 25 Jun 2024₹1.7t₹198.0b₹23.7b34x73.6x8.8x
Thu, 23 May 2024₹1.6t₹193.7b₹21.6b33.9x74.3x8.3x
Sat, 20 Apr 2024₹1.4t₹168.5b₹18.6b28.7x75.4x8.3x
Mon, 18 Mar 2024₹1.3t₹168.5b₹18.6b29x71.3x7.9x
Wed, 14 Feb 2024₹1.4t₹168.5b₹19.6b33.7x72.5x8.4x
Fri, 12 Jan 2024₹1.4t₹155.9b₹18.1b24.6x79.9x9.3x
Sun, 10 Dec 2023₹1.4t₹155.9b₹18.1b23.2x75.1x8.7x
Tue, 07 Nov 2023₹1.3t₹156.1b₹19.9b23.3x65.7x8.4x
Thu, 05 Oct 2023₹1.4t₹154.7b₹19.7b26.4x71.8x9.1x
Sat, 02 Sep 2023₹1.4t₹154.7b₹19.7b26.2x68.9x8.8x
Price to Earnings Ratio

68.9x


Total Market Cap: ₹1.4tTotal Earnings: ₹19.7bTotal Revenue: ₹154.7bTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Clinical Research and Equipment Industry Price to Earnings3Y Average 75x202420252026
Current Industry PE
  • Investors are optimistic on the Indian Life Sciences Tools and Services industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 81.3x which is higher than its 3-year average PE of 75.0x.
  • The 3-year average PS ratio of 9.0x is lower than the industry's current PS ratio of 10.5x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 35% per year over the last three years.
  • Revenues for these companies have grown 34% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Indian Clinical Research and Equipment compare with similar industries?

IN Market0.48%
Healthcare0.37%
Life Sciences1.01%
Clinical Research and Equipment1.01%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
DIVISLAB Divi's Laboratories₹9.03k5.4%
+₹123.4b		45.8%PE81.9x
ANTHEM Anthem Biosciences₹923.054.7%
+₹23.2b		10.4%PE90.3x
530239 Suven Life Sciences₹371.8511.9%
+₹10.4b		68.8%PS1112.6x
SAILIFE Sai Life Sciences₹1.46k2.7%
+₹8.2b		69.7%PE85.7x
SYNGENE Syngene International₹411.153.6%
+₹5.7b		-36.6%PE74.1x

Latest News

511509
₹18.62
Vivo Bio Tech
7D
-2.3%
1Y
-49.8%
SAILIFE
₹1,461.00
Sai Life Sciences
7D
2.7%
1Y
69.7%
Narrative Update • Aug 24

SAILIFE: Upcoming Board Results And Revised Assumptions Will Guide Measured Outlook

Analysts have raised their price target for Sai Life Sciences from ₹1,369.17 to ₹1,552.67, citing updated assumptions for revenue growth, profit margin and future P/E as the key drivers of this revision. What's in the News for Sai Life Sciences Sai Life Sciences has scheduled a Board Meeting for 6 Aug 2026 to review and approve its unaudited standalone and consolidated financial results.
DIVISLAB
₹9,025.00
Divi's Laboratories
7D
5.4%
1Y
45.8%
Narrative Update • Aug 20

DIVISLAB: Upcoming June Quarter Results Will Support Bullish Outlook

Analysts have adjusted their price target on Divi's Laboratories from about ₹8,795 to about ₹10,953, reflecting updated views on its fair value, discount rate, revenue growth and profit margin assumptions, as well as the P/E they apply to the stock. What’s in the News for Divi's Laboratories Divi's Laboratories has scheduled a Board meeting on August 1, 2026.
DCAL
₹175.27
Dishman Carbogen Amcis
7D
1.7%
1Y
-35.5%
INNOVACAP
₹1,031.25
Innova Captab
7D
-0.8%
1Y
13.1%
Analysis Article • Aug 15

Earnings Beat: Innova Captab Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Innova Captab Limited ( NSE:INNOVACAP ) investors will be delighted, with the company turning in some strong numbers...
526853
₹91.23
Bilcare
7D
-0.6%
1Y
41.2%
538837
₹74.04
Jeevan Scientific Technology
7D
-0.3%
1Y
87.4%
SYNGENE
₹411.15
Syngene International
7D
3.6%
1Y
-36.6%
Narrative Update • Aug 14

SYNGENE: Earnings Guidance And Margin Outlook Will Pressure Future Returns

Analysts have trimmed their price target for Syngene International from ₹410 to ₹340, citing updated assumptions on revenue growth, profit margins, and a lower future P/E multiple in their valuation work. What’s in the News for Syngene International Syngene International issued earnings guidance for fiscal 2027, indicating an expected single digit decline in revenue in rupee terms and EBITDA margins in the mid 20% range.
AKUMS
₹766.10
Akums Drugs and Pharmaceuticals
7D
1.7%
1Y
60.6%
Narrative Update • Aug 11

AKUMS: Upcoming Board Schedule And Special Dividend Will Shape Earnings Outlook

Analysts have lifted their price target on Akums Drugs and Pharmaceuticals from ₹730 to ₹780, citing updated estimates that reflect the new fair value, an adjusted discount rate, revised revenue growth assumptions, higher profit margin forecasts and a lower future P/E multiple. What's in the News Akums Drugs and Pharmaceuticals has scheduled a board meeting on Aug 08, 2026, at 13:30 Indian Standard Time to consider and approve the unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026.
TARSONS
₹342.65
Tarsons Products
7D
-0.1%
1Y
7.9%
539267
₹10.81
Samsrita Labs
7D
-7.4%
1Y
-46.9%
544184
₹127.55
Borosil Scientific
7D
-1.5%
1Y
-8.1%
530239
₹371.85
Suven Life Sciences
7D
11.9%
1Y
68.8%
INDGN
₹569.70
Indegene
7D
0.7%
1Y
1.4%
Analysis Article • Aug 03

Indegene Limited (NSE:INDGN) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

It's been a good week for Indegene Limited ( NSE:INDGN ) shareholders, because the company has just released its latest...
ONESOURCE
₹1,483.60
OneSource Specialty Pharma
7D
-2.4%
1Y
-20.3%
Analysis Article • Jul 29

Analysts Are Updating Their OneSource Specialty Pharma Limited (NSE:ONESOURCE) Estimates After Its First-Quarter Results

It's been a good week for OneSource Specialty Pharma Limited ( NSE:ONESOURCE ) shareholders, because the company has...
ANTHEM
₹923.05
Anthem Biosciences
7D
4.7%
1Y
10.4%
New Narrative • Jul 28

Capacity Expansion And Modalities Shift Will Support Stronger Long-Term Earnings Visibility

Catalysts About Anthem Biosciences Anthem Biosciences is a contract research, development and manufacturing organization with a large focus on CRDMO services and specialty ingredients across small molecules, peptides, fermentation and related modalities. What are the underlying business or industry changes driving this perspective?